Latest California Healthline Stories
Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
Journalists Tackle Delta Variant, Hospital Prices and Public Health Spending
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Effort to Decipher Hospital Prices Yields Key Finding: Don’t Try It at Home
Your dutiful columnist tried to make use of a federal “transparency” rule to compare the prices of common medical procedures in two California health care systems. It was a futile exercise.
Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say
The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.
‘An Arm and a Leg’: Tips for Fighting Medical Bills from ProPublica’s Marshall Allen
Veteran health journalist Marshall Allen has been exposing health care grifters for years. Now he’s written a book about how to fight them. Host Dan Weissmann spoke with Allen about some of the best tips from “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
Rural Ambulance Services Are in Jeopardy as Volunteers Age and Expenses Mount
Experts say rural communities must find new models to keep emergency services afloat as more 911 calls go unanswered.
Hospital Prices Must Now Be Transparent. For Many Consumers, They’re Still Anyone’s Guess.
A Trump administration rule mandating that hospitals disclose true prices on their websites took effect this year. But compliance is spotty and even when the data is public, it’s hard to find and understand.
KHN’s ‘What the Health?’: Un-Trumping the ACA
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act, in an effort to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive new drug that might or might not slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of The Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
States Step Up Push to Regulate Pharmacy Drug Brokers
In an ongoing effort to control prescription drug costs, states are targeting the companies that mediate deals among drug manufacturers, health insurers and pharmacies. The pharmacy benefit managers say they negotiate lower prices for patients, yet the nitty-gritty occurs largely behind a curtain that lawmakers are trying to pull back.
A Hospital Charged $722.50 to Push Medicine Through an IV. Twice.
A college student never got an answer for what caused her intense pain, but she did get a bill that totaled $18,736 for an ER visit. She and her mom, a nurse practitioner, fought to understand all the charges.